Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2026-03-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于子公司GenSci161注射液境内生产药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High-tech Industry Group Co., Ltd. regarding the acceptance of a clinical trial application for a drug developed by its subsidiary. It contains no financial data, no detailed financial performance, no management discussion of financial results, and no regulatory certifications. The document is an announcement of a regulatory approval event related to clinical trial acceptance, not a financial report or management report. It is a typical regulatory announcement informing investors about a material event affecting the company. The document length is short (1368 characters), and it is clearly an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-02 Chinese
关于子公司GenSci141软膏境内生产药品注册临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the approval of a clinical trial application for a pharmaceutical product by its subsidiary. It details the product, the approval by the National Medical Products Administration, and the potential impact and risks. The document is short (1101 characters) and serves as a formal announcement of regulatory approval rather than a financial or operational report. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for regulatory announcements that do not fit other specific categories.
2026-02-24 Chinese
关于子公司注射用GenSci136境内生产药品注册临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High & New Technology Industries (Group) Co., Ltd. regarding the approval of a clinical trial application for a drug developed by its subsidiary. It details the drug's background, clinical trial approval, and potential impact. The document is relatively short (1689 characters) and serves as a formal announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed data. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not related to board changes, voting results, or capital changes. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about clinical trial approval, which is a material event but not a financial report or other specific filing type.
2026-02-09 Chinese
关于子公司注射用GenSci136境内生产药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High-tech Industry Group Co., Ltd. regarding the acceptance of a clinical trial application for a drug developed by its subsidiary. It details the drug's background, clinical trial acceptance by the National Medical Products Administration, and potential impact on the company. The document is short (1694 characters) and primarily serves as a regulatory announcement about the acceptance of a clinical trial application, not a financial report or detailed regulatory filing. It does not contain financial data, audit information, or management discussion. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial acceptance.
2026-02-03 Chinese
关于子公司GS3-007a干混悬剂境内生产药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High & New Technology Industry Group Co., Ltd. regarding the acceptance of a clinical trial application for a drug developed by its subsidiary. It includes details about the drug, the clinical trial application acceptance by the National Medical Products Administration, and the impact on the company. The document is short (1276 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report but an announcement of a regulatory event related to clinical trial acceptance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-02 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2025 年度业绩预告' which translates to '2025 Annual Performance Forecast'. It provides an earnings forecast for the fiscal year 2025, including expected net profit and reasons for changes compared to the previous year. It explicitly states that the data is preliminary, unaudited, and that detailed financial data will be disclosed in the 2025 Annual Report. The document is relatively short (1672 characters) and serves as a performance forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only, not a full annual report or audited financial statements. FY 2025
2026-01-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.